ERBB2 and breast cancer: As shown in Figure 6d–g, knock-down of TRIB3 rendered both MCF7 and BT474 cells more resistant to the treatment with these agents further supporting the idea that enhanced TRIB3 expression may facilitate the response to these therapies in both HER2- and HER2+ luminal BC cells.